US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy

2Seventy Bio

15/03/2024 21:02

March 15 (Reuters) - Advisers to the U.S. Food and Drug
Administration on Friday voted in favor of allowing the use of
Bristol Myers Squibb's  BMY.N  cell therapy as an earlier
treatment for a type of blood cancer.
    The panel voted 8-3 in favor that benefits of Bristol's
Abecma outweighed the risks of the therapy when given as an
earlier treatment.

 (Reporting by Bhanvi Satija and Sneha S K in Bengaluru; Editing
by Shailesh Kuber)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788))